Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
5/29/2020 2402: Disease Classification Added Added clarification that chromosomal microarrays / chromosomal genomic arrays should be reported within the FISH assessments data fields.
5/28/2020 2450: Post-TED Added Added clarification that chromosomal microarrays / chromosomal genomic array should be reported within the FISH assessment data fields.
5/28/2020 2450: Post-TED Removed For question 84, removed instructions allowing chromosomal microarrays / chromosomal genomic array to be reported in the molecular assessment data fields. These assessments should not be reported within the molecular assessment data fields.
5/28/2020 2400: Pre-TED Modify Provided additional clarification on how to report the GFR if a range, “< X” or “> X” is listed and when the GFR calculator may be used.
5/21/2020 2400: Pre-TED Modify Provided additional clarification on how to report the ordered dose when pharmacokinetic testing is performed in question 129.
5/21/2020 2450: Post-TED Modify Provided clarification on how to report molecular abnormalities identified by other methods of assessment.
5/21/2020 4000: Cellular Therapy Essential Data Pre-Infusion Modify Q106- Clarified the instructions for reporting drug dose: Report the total prescribed dose that was actually given of the drug selected in question 104. Drug doses can be reported with one decimal place.
5/20/2020 4000: Cellular Therapy Essential Data Pre-Infusion Modify Q104- Clarified the instructions for reporting drug dose: For each drug listed, checking the box will indicate it was given as part of the lymphodepleting therapy used prior to the cellular therapy infusion. Report the total prescribed dose of each drug that was actually given. Do not report the prescribed dose or the daily dose. The pharmacy record or Medication Administration Record (MAR) should be used for determining the exact total dose given.
5/19/2020 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion Modify For question 13, specified that a constant temperature is usually found in cord blood shipping containers.
5/19/2020 2402: Disease Classification Modify Updated disease indication mentioned in guidance for answering question 101 from AML to ALL.
5/19/2020 2018: LYM Pre-Infusion Add Added specification that questions 62 and 146 should be answered for all Hodgkin histologies.
5/14/2020 AML Response Criteria Modify Modified guidance on recipients with MDS that transformed to AML (red box at the beginning) to include more context on guidance.
5/13/2020 2402: Disease Classification Modify Updated the following disease status criteria for hairy cell leukemia for question 378: Complete Remission, Stable Disease, and Progressive Disease.
5/13/2020 Multiple Myeloma Response Criteria Add Added blue information box in Complete Response section providing guidance on Serum or Urine Immunofixation.
5/13/2020 2400: Pre-TED Remove Removed the word “proven” from question 92 guidance. Removed verbiage from paragraphs defining “proven”.
5/13/2020 CML Response Criteria Add Added blue information box in the beginning, providing guidance on disease status tracking.
5/13/2020 2100: Post-HCT Follow-Up Modify For question 428-436, under Date of Diagnosis, updated first sentence to say “Report the specimen collection date of the positive microbiology culture or laboratory report as the diagnosis date”.
5/13/2020 2402: Disease Classification Modify Updated questions 23 and 115 so that, wherever indicated, “microarray” is now “chromosomal microarray”.
5/13/2020 2402: Disease Classification Modify Updated question 389 to include criteria the the PET or combination PET / CT scan must meet to answer “yes” for this question.
5/11/2020 4000: Cellular Therapy Essential Data Pre-Infusion Add Included instructions for questions that were added to the form (questions 111-113) intended to capture information on COVID-19 (SARS-CoV-2) infections.
5/11/2020 2450: Post-TED Add Added in questions 50-51 to capture information regarding COVID-19 (SARS-CoV-2) infections.
5/10/2020 MDS Response Criteria Modify Removed the MPN response criteria to align with the separation of the MDS and MPN disease-specific forms.
5/10/2020 MPN Response Criteria Add Separated the MPN response criteria to align with the new MPN disease-specific forms.
5/10/2020 2149: Respiratory Virus Post-Infusion Data Add Version 1 of the 2149: Respiratory Virus Post-Infusion Data section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2149.
5/10/2020 2157: Myeloproliferative Neoplasm (MPN) Post-HCT Add Version 1 of the 2157: MPN Post-HCT section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2157.
5/10/2020 2057: Myeloproliferative Neoplasm (MPN) Pre-Infusion Add Version 1 of the 2057: MPN Pre-Infusion section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2057.
5/9/2020 MDS Post-HCT Modify Version 3 of the 2114: MDS Post-HCT section of the Forms Instruction Manual released. Version 3 corresponds to revision 4 of the Form 2114.
5/9/2020 2014: MDS Pre-Infusion Modify Version 3 of the 2014: MDS Pre-Infusion section of the Forms Instructions Manual released. Version 3 corresponds to revision 4 of the Form 2014.
5/9/2020 2400: Pre-TED Modify Version 6 of the 2400: Pre-TED section of the Forms Instruction Manual released. Version 6 corresponds to revision 7 of the Form 2400.
5/9/2020 2402: Disease Classification Modify Version 5 of the 2402: Pre-TED Disease Classification section of the Forms Instructions Manual released. Version 5 corresponds to revision 5 of the Form 2402.
5/8/20 2541: Inotuzumab Ozogamacin (Besponsa™) Supplemental Data Modify Updated units of measure for Questions 7-8 verbiage to “m/m 2”.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 124-125 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 329-330 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 326-327 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 127-128 to document unit of measure to the nearest tenth.
5/8/2020 2016: PCD Pre-Infusion Add Added guidance for question 139-140 to document unit of measure to the nearest tenth.
5/8/2020 2016: PCD Pre-Infusion Add Added guidance for question 142-143 to document unit of measure to the nearest tenth.
5/7/2020 2016: PCD Pre-Infusion Add Added guidance for question 192: “Question 192 is disabled and should not be answered. This question will be removed when the form is next revised”.
5/7/2020 2402: Disease Classification Modify Modified guidance on answering question 278, guidance now states “Question 278 is disabled and should not be answered. This question will be removed when the form is next revised”.
5/7/2020 2100: Post-HCT Follow-Up Add For questions 69-74, added phrase after bulleted items stating “If testing was performed as captured in question 64…”.
5/7/2020 2100: Post-HCT Follow-Up Add For question 64, added sentence “Questions 69-74 will then be disabled”.
5/7/2020 2400: Pre-TED Add For question 11, added the following guidance on zip codes: The zip or postal code is required for USA residents. The postal code is optional for Canadian residents. The question can be answered or left blank without error for Canadian residents.
5/5/2020 4100: Cellular Therapy Essential Data Follow-Up Modify Added a clarification to the blue note box below question 9: If the primary disease reported is Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), or Multiple Myeloma (MM) best response should not be answered on this form. It will be captured on the corresponding disease form. The question should be left blank and please override the error at this time.
5/5/2020 4100: Cellular Therapy Essential Data Follow-Up Remove Removed blue note box: “This section will be disabled when disease specific forms are also being completed.”
4/7/2020 2450: Post-TED Add For question 41, added guidance on the intent of the question.
4/7/2020 2100: Post-HCT Follow-Up Add For question 303, added guidance on the intent of the question.
4/7/2020 2128: Aplastic Anemia Post-HCT Modify Updated red blood cell independence instructions (question 1) to make determinations based on the date of contact rather than the date of last report. Also added guidance that if the recipient was transfusion independent for part of the reporting period, but then is dependent again at the end of the reporting period, select “no” and continue to question 2.
4/7/2020 2553: VOD/SOS Add Added reporting guidance for scenario when drugs given for liver prophylaxis (red information box).
4/7/2020 2450: Post-TED Add Added guidance on reporting estimated dates after question 18 (blue information box).
4/7/2020 2100: Post-HCT Follow-Up Add Added guidance on reporting estimated dates (in blue informational box).
4/7/2020 2018: LYM Pre-Infusion Add Added sentence after question 80-81 stating Documentation from an RN who has been trained and authorized to determine performance scores may also be used.
4/7/2020 4000: Cellular Therapy Essential Data Pre-Infusion Add For question 109-100, added the following guidance for Karnofsky/Lansky scores: Documentation from an RN who has been trained and authorized to determine performance scores may also be used.
4/7/2020 2400: Pre-TED Add For question 85-86, added the following guidance on Karnofsky/Lansky score documentation: Documentation from an RN who has been trained and authorized to determine performance scores may also be used.
4/7/2020 Multiple Myeloma Response Criteria Add Under light chain only myeloma CR criteria, added negative immunofixation on both serum and urine samples (added serum to criteria).
4/7/2020 2018: LYM Pre-Infusion Modify Updated question numbers in section Q224-233: Disease Assessment at the Failure of the 1st Line of Therapy.
4/7/2020 2402: Disease Classification Add Added blue informational box before questions 23, 50, 77, 115, and 153 providing clarification on questions capturing molecular markers.
4/7/2020 2402: Disease Classification Remove Removed erythropoietic protoporphyria (EPP) as an example of another disease for question 364. Example now given is dystrophic epidermolysis bullosa (DEB).
4/7/2020 2402: Disease Classification Add Added red warning box with guidance on erythropoietic protoporphyria (EPP) after question 1.
4/6/2020 2400: Pre-TED Remove Removed the word “unrelated” from question 60, which now reads NMDP donor ID.
4/6/2020 Amyloidosis Response Criteria Add Added guidance on Free Light Chain Ratios.
4/6/2020 Plasma Cell Leukemia Response Criteria Add Added guidance on Free Light Chain Ratios.
4/6/2020 Multiple Myeloma Response Criteria Add Added guidance (blue box) on normal ranges for Free Light Chain Ratios.
4/6/2020 2814: Indication for CRID Assignment Add Added sentence to question 5 providing guidance on when to select ‘no’.
4/6/2020 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion Modify In section Q144-170: Donor/Infant Demographic Information, moved question 147 to question 159.
4/6/2020 2000: Recipient Baseline Remove Question 38 – removed CMV exception for serologic tests.
4/6/2020 2450: Post-TED Modify Updated hyperlink in Lost to Follow Up section for the Lost to Follow Up Tool.
4/6/2020 2450: Post-TED Remove Removed sentence in Lost to Follow Up section in introduction – If your center receives documented information that a recipient is alive or dead, the form should be filled out with the recipient survival status.
4/6/2020 2100: Post-HCT Follow-Up Modify Updated hyperlink in Lost to Follow Up section for the Lost to Follow Up Tool.
4/6/2020 2100: Post-HCT Follow-Up Remove Removed sentence in Lost to Follow Up section in introduction – If your center receives documented information that a recipient is alive or dead, the form should be filled out with the recipient survival status.
4/6/2020 Appendix A: Abbreviations and Definitions Add Added definitions for CPI, CTA, CVDR, and TCSA.
3/27/2020 2016: PCD Pre-Infusion Modify Modified sentence referring reader to question 188 for POEMS syndrome to recipient having a primary disease of monoclonal gammopathy of renal significance (MGRS) in the section Q157-187: Pre-HCT Therapy.
3/27/2020 2116: PCD Post-Infusion Modify Updated question numbers found in guidance for answering questions 54 and 91 in the section Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response.
3/27/2020 2116: PCD Post-Infusion Modify Updated question numbers found in guidance for answering questions 256 and 293 in the section Q253-311: Current Status of Amyloidosis for this Reporting Period.
3/27/2020 2116: PCD Post-Infusion Add Added sentence for guidance on answering question 251 in that says This question will not be enabled if the primary disease for transplant is monoclonal gammopathy of renal significance (MGRS). in the section Q211-252: Disease Status at the Time of Evaluation for this Reporting Period.
3/27/2020 2116: PCD Post-Infusion Add Added sentence for guidance on answering question 3 in that says This question will not be enabled if the primary disease for transplant is monoclonal gammopathy of renal significance (MGRS). in the section Q3-53: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy.
3/27/2020 2402: Disease Classification Modify Replaced “>” with “>/=” for guidance for question 324 in section Q306-339: Inherited Abnormalities of Erythrocyte Differentiation or Function.
3/27/2020 2402: Disease Classification Add Added sentence for question 298 in section Q254-301: Multiple Myeloma / Plasma Cell Disorder, stating This question will not be enabled if the primary disease for transplant is monoclonal gammopathy of renal significance (MGRS).
3/23/2020 Appendix J: Reporting Comorbidities Add Added link for determining pediatric BMI-for-age for obesity guidelines.
3/23/2020 2400: Pre-TED Modify In the Q88-113: Comorbid Conditions section, updated cardiac reporting guideline for congestive heart failure to include guidance on LVEF.
3/23/2020 2016: PCD Pre-Infusion Add Added guidance on LV straing percentage to questions 77-78 and 262-263.
3/23/2020 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion Modify Added guidance to questions 46 – 47, 58-59, 64-65, 70-71, and 76-77 regarding scenarios where center’s laboratory assay only measures viable cells.
3/23/2020 Amyloidosis Response Criteria Add Added definition for Very Good Partial Response (VGPR).
3/23/2020 2400: Pre-TED Add In the Q88-113: Comorbid Conditions section, added guidance to obesity reporting guideline for calculating BMI-for-age for pediatric patients.
3/23/2020 2402: Disease Classification Modify Updated “CLL” to “NHL” in the Common Disease Transformations table in section Q1-2: Primary Disease for HCT / Cellular Therapy.
3/23/2020 Appendix J: Reporting Comorbidities Add Added “(regardless of an LVEF >50% at the start of preparative regimen)” after congestive heart failure bullet point.
3/23/2020 2116: PCD Post-Infusion Add Added information about the LV strain percentage in the Q253-311: Current Status pf Amyloidosis for this Reporting Period section for questions 265-266.
3/23/2020 2116: PCD Post-Infusion Add Added information about the LV strain percentage in the Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response section for questions 63-64.
3/20/2020 2400: Pre-TED Modify In the Q46-83: Donor Information section, updated instructions for question 51 to include more specific criteria for a genetically modified product.
3/20/2020 2018: LYM Pre-Infusion Add Added guidance in introduction to Q166-223: Pre-HCT Therapy on scenario where recipient’s lymphoma histology transforms between diagnosis and start of preparative regimen.
3/11/2020 2128: Aplastic Anemia Post-HCT Modify Updated the platelet transfusion independence instructions by removing (strike through) and adding (red) text as indicated below:
Indicate if the recipient was platelet transfusion independent since the date of the last report on the date of contact for the current reporting period. A general guideline for platelet transfusion independence is that platelet transfusions have not been required for seven or more days.
If the recipient was platelet transfusion independent since the date of the last report on the date of contact, select “yes” and continue with question 5.
If the recipient was not platelet transfusion independent since the date of the last report on the date of contact, select “no” and continue with question 4.
If the recipient is transfusion independent for a portion of the reporting period, but then is dependent again at the end of the reporting period, select “no” and continue with question 4.
If it is unknown if the recipient was platelet transfusion independent since the date of the last report on the date of contact, select “unknown” and continue with question 5.
3/6/2020 2100: Post-HCT Follow-Up Add Added sentence in guidance for question 177 in section Q131-233: Acute Graft vs. Host Disease. Sentence provides guidance on scenario when maximum overall grade was achieved, but specific organ staging varies.
3/6/2020 2450: Post-TED Remove Removed “reasons other than” in guidance given on Cellular Therapy reporting for question 115 in section Q106-116: Relapse or Progression Post-HCT.
3/6/2020 2402: Disease Classification Modify Updated “report the value” to “report the percent” after question after questions 78-89 in section Q3-95: Acute Myelogenous Leukemia.
3/6/2020 2400: Pre-TED Modify In Q114-128: Pre-HCT Preparative Regimen section, updated instructions for question 124 – 125 to report drug doses to the nearest tenth.
3/6/2020 2400: Pre-TED Modify In Q114-128: Pre-HCT Preparative Regimen section, updated instructions for question 115 to report weight to the nearest tenth of a kilogram.
3/6/2020 2400: Pre-TED Modify Moved “arrhythmia” designation after question 93 in sectionQ88 – 113: Comorbid Conditions in the Documented Medical History list. Removed “other” listing after “Current Diagnosis at the Time of Pre-HCT Evaluation” list.
3/6/2020 Appendix J: Reporting Comorbidities Add Added “mild” specification in valve regurgitation listing for table of conditions that are not relevant transplant outcomes or risk.
3/6/2020 2450: Post-TED Add Added sentence in second paragraph of Question 106-116: Relapse or Progression Post-HCT regarding scenario where recipient receives a chemotherapy agent that is not listed.
3/5/2020 “2100: Post-HCT Follow-Up”:“https://www.cibmtr.org/manuals/fim/1/en/topic/2100 Modify Changed survival status text after Question 1 in section “”:https://www.cibmtr.org/manuals/fim/1/en/topic/q1-7-vital-statusQ1-5: Vital Status. Instead of completing the POst-TED Form reporting only survival status, the Survival Tool in the CIBMTR Data Management Guide should be used (link to Survival Tool provided after question 1).
3/5/2020 2450: Post-TED Modify Changed survival status text after Question 1 in section Q1-6: Survival. Instead of completing the POst-TED Form reporting only survival status, the Survival Tool in the CIBMTR Data Management Guide should be used (link to Survival Tool provided after question 1).
3/5/2020 2100: Post-HCT Follow-Up Add Added “demonstrated on labial biopsy (labial biopsy not required)” after question 303 in section Chronic Graft vs. Host Disease.
3/5/2020 2450: Post-TED Add Added “demonstrated on labial biopsy (labial biopsy not required)” after question 41 in section Graft versus Host Disease.
3/5/20 ALL Post-Infusion Add In section Disease Assessment at the Time of Best Response to HCT, guidance for question 1 on scenarios where 2111 is completed for both the cellular therapy and HCT track.
3/3/2020 2450: Post-TED Modify Added “allogeneic HCT” and “allogeneic HCT recipient whose” in the blue note box at the beginning of Q58-77: Chimerism Studies.
3/2/2020 Cellular Therapy Manuals Modify Updated and clarified when autologous cellular therapy data can be collected in the context of patient consent for research
3/2/2020 4100: Cellular Therapy Essential Data Follow-Up Add Added the following sentence to reporting instruction for question 158-160: Other grade 4 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.
3/2/2020 4100: Cellular Therapy Essential Data Follow-Up Add Added the following sentence to reporting instruction for question 151-153: Other grade 3 toxicities / symptoms that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.
3/2/2020 4100: Cellular Therapy Essential Data Follow-Up Add Added the following sentence to reporting instruction for question 145-146: Other toxicities that are reported should be related to the cellular therapy infusion that are documented in the medical record as clinically important and relevant and do not fit into another category listed on this form.
2/27/2020 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion Modify Updated the text for questions 163-165 as indicated below (removed text is struck out and added text is in red):
If the recipient donor did not give autologous blood transfusion units, select “no” and continue with question 166.
2/21/2020 2110: AML Post-Infusion Modify Modified question 51-52 in the Disease Detection Since Date of Last Report section.
2/19/2020 Appendix G: Tracking Disease Status for Multiple Myeloma Modify Updated this appendix and the linked documents to remove the Near Complete Remission (nCR) disease response criteria. This disease response was removed in accordance with revision 4 of the Forms 2016/2116.
2/19/2020 2011: ALL Pre-Infusion Modify Updated number from 64 to 20 on ALL Pre-Infusion main page.
2/19/2020 2010: AML Pre-Infusion Modify Updated 69 to 32 on 2010: AML Pre-Infusion main page.
2/19/2020 2118: LYM Post-Infusion Data Modify Changed the instruction for for reporting question 89. This was previously updated in question 87 (see below) but modified the following instruction to question 89 (for additional clarity) by removing (strike through) and adding (red) text as indicated below.
The center does not need to repeat all disease-specific assessments (biopsies, i.e., CT (radiographic) or PET scans, labs) each reporting period in order to complete current disease status data fields. Once a particular disease status is achieved, the center can continue reporting that disease status (based on labs / clinical assessments) until there is evidence of relapse / progression. If a disease-specific assessment did not occur during this time period, please report the date of any disease related assessment (e.g. clinical assessments, labs, etc.) as the date assessed (Q88 or Q90) regardless of what the parent question states about the specific CT (radiographic) or PET criteria.
2/19/2020 2018: LYM Pre-Infusion Add Added information after Questions 1-2 and Questions 83-85 on double-hit or triple-hit lymphomas.
2/19/2020 2402: Disease Classification Add Added information about double-hit or triple-hit lymphomas to questions 236-237 in the Hodgkin and Non-Hodgkin Lymphoma section.
2/19/2020 2118: LYM Post-Infusion Data Add Added guidance in Disease Assessment at the Time of Best Response to HCT or Cellular Therapy, after question 1, on scenarios where the form is completed for both the cellular therapy and HCT tracks.
2/19/2020 ALL Post-Infusion Add In section Disease Assessment at the Time of Best Response to HCT, added scenarios in introduction for instances when form is completed for both the cellular therapy track and HCT track.
2/19/2020 2450: Post-TED Add Added information on tandem transplant in the introduction to the Disease Assessment at the Time of Best Response to HCT section. Added example to question 78.
2/19/2020 2450: Post-TED Add Added information on tandem transplant in the introduction to the Current Disease Status section. Added examples to question 117.
2/14/2020 2100: Post-HCT Follow-Up Add Added the following sentence to reporting instruction for question 486-487: If the recipient was intubated multiple times within the reporting period, please report the first date of intubation.
2/14/2020 2100: Post-HCT Follow-Up Add Added the following sentence to reporting instruction for question 488-489: If the recipient was extubated multiple times within the reporting period, please report the last date of extubation.
2/14/2020 Form 2111, Q95-130: Disease Status at the Time of Evaluation for This Reporting Period Modify Updated “51 – 84” to “48 – 80” in question 95.
2/10/2020 2804: CIBMTR Research ID Assignment Form Remove Removed the warning boxes above questions 8, 9, and 10 indicating that the fields were disabled. These fields were enabled at the time of the Winter 2020 release.
2/6/2020 4100: Cellular Therapy Essential Data Follow-Up Modify Added table to display organ/system and applicable symptoms for grade 3 & 4 organ toxicities.
2/3/2020 2402: Disease Classification Modify Updated the instructions in the multiple myeloma section of the Disease Classification (2402) form to reflect that all cytogenetic abnormalities reported on the updated version of the form should be at diagnosis. Previous revisions of this form captured all cytogenetic abnormalities prior to the start of the preparative regimen.
1/30/2020 Appendix J: Reporting Comorbidities Remove Removed information on reporting “Other comorbidities” as this is no longer an option on the new Pre-TED (2400) form.
1/29/2020 2814: Indication for CRID Assignment Add Added the following instruction for how to report the date of transplant for intrauterine transplants:
Intrauterine Transplants
For intrauterine transplants, report the date of birth as the date of transplant to avoid errors from occurring in FormsNet3SM.
1/29/2020 4100: Cellular Therapy Essential Data Follow-Up Modify Clarified best response valid options in Table 1.
1/27/2020 2100: Post-HCT Follow-Up Modify Added the following reporting instruction for the date of contact (question 1) in red below:
Enter the date of actual contact with recipient to determine medical status for this follow-up report. Acceptable evaluations include those from the transplant center, referring physician, or other physician currently assuming responsibility for the recipient’s care. Please capture a physician evaluation that falls within the appropriate range, if possible, rather than other types of patient contact that may be closer to the actual time point. If an evaluation was not performed at Day+100, at 6 months, or on the HCT anniversary, choose the date of the visit closest to the actual time point.
1/24/2020 2400: Pre-TED Modify Version 5 of the 2400: Pre-TED section of the Forms Instruction Manual released. Version 5 corresponds to revision 6 of the Form 2400.
1/24/2020 2402: Disease Classification Modify Version 4 of the 2402: Disease Classification section of the Forms Instruction Manual released. Version 4 corresponds to revision 4 of the Form 2402.
1/24/2020 2450: Post-TED Modify Version 4 of the 2450: Post-TED section of the Forms Instruction Manual released. Version 4 corresponds to revision 5 of the Form 2450.
1/24/2020 2000: Recipient Baseline Modify Version 3 of the 2000: Recipient Baseline section of the Forms Instruction Manual released. Version 3 corresponds to revision 5 of the Form 2000.
1/24/2020 2004: Infectious Disease Markers Modify Version 4 of the 2004: Infectious Disease Markers section of the Forms Instruction Manual released. Version 4 corresponds to revision 5 of the Form 2004.
1/24/2020 2005: Confirmation of HLA Typing Modify Version 4 of the 2005: Confirmation of HLA Typing section of the Forms Instruction Manual released. Version 4 corresponds to revision 7 of the Form 2005.
1/24/2020 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion Modify Version 4 of the 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion section of the Forms Instruction Manual released. Version 4 corresponds to revision 5 of the Form 2006.
1/24/2020 2016: PCD Pre-Infusion Modify Version 3 of the 2016: Plasma Cell Disorders (PCD) Pre-Infusion Data section of the Forms Instruction Manual released. Version 3 corresponds to revision 4 of the Form 2016.
1/24/2020 2116: PCD Post-Infusion Modify Version 3 of the 2016: Plasma Cell Disorders (PCD) Post-Infusion Data section of the Forms Instruction Manual released. Version 3 corresponds to revision 4 of the Form 2116.
1/24/2020 2542: Mogamulizumab Supplemental Data Collection Add Version 1 of the 2542: Mogamuluizumab Supplemental Data Collection section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2542.
1/24/2020 4000: Cellular Therapy Essential Data Pre-Infusion Modify Version 4 of the 4000: Cellular Therapy Essential Data Pre-Infusion section of the Forms Instruction Manual released. Version 4 corresponds to revision 6 of the form 4000.
1/24/2020 4003: Cellular Therapy Product Modify Version 3 of the 4003: Cellular Therapy Product section of the Forms Instruction Manual released. Version 3 corresponds to revision 3 of the Form 4003.
1/24/2020 4006: Cellular Therapy Infusion Modify Version 4 of the 4006: Cellular Therapy Infusion section of the Forms Instruction Manual released. Version 4 corresponds to revision 4 of the Form 4006.
1/24/2020 4100: Cellular Therapy Essential Data Follow-Up Modify Version 5 section of the Forms Instruction Manual released. Version 5 corresponds to revision 5 of the Form 4100.
12/16/2019 F4100 Cellular Therapy Essential Data Follow-up Modify Added the following note about DCI/DLI infusions in questions 14 and 16. Check “not applicable” for DCI/DLI infusions where a preparative regimen was not given
Last modified: May 29, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.